Literature DB >> 27911008

Comparison of neuropathology in Parkinson's disease subjects with and without deep brain stimulation.

Gian D Pal1, Bichun Ouyang1, Geidy Serrano2, Holly A Shill2, Christopher Goetz1, Glenn Stebbins1, Leo Verhagen Metman1, Erika Driver-Dunckley3, Shyamal H Mehta3, John N Caviness3, Marwan N Sabbagh2, Charles H Adler2,3, Thomas G Beach2,3.   

Abstract

BACKGROUND: The aim of this postmortem study was to compare, in Parkinson's disease subjects with and without bilateral subthalamic nucleus deep brain stimulation (STN-DBS), the loss of pigmented neurons within the substantia nigra and pathological alpha-synuclein density within the SN and other brain regions.
METHODS: PD subjects were identified from the Arizona Study of Aging and Neurodegenerative Disorders database (STN-DBS = 11, non-DBS = 156). Pigmented neuron loss scores within the substantia nigra as well as alpha-synuclein density scores within the substantia nigra and 9 other brain regions were compared, the latter individually and in summary as the Lewy body brain load score.
RESULTS: DBS subjects had higher alpha-synuclein density scores within the substantia nigra, olfactory bulb, and locus ceruleus, as well as higher total Lewy body brain load scores when compared with non-DBS subjects. No differences in substantia nigra pigmented neuron loss scores were found.
CONCLUSIONS: STN-DBS subjects tend to have higher alpha-synuclein density scores, but do not have a differential loss of substantia nigra pigmented neurons.
© 2016 International Parkinson and Movement Disorder Society. © 2016 International Parkinson and Movement Disorder Society.

Entities:  

Keywords:  Lewy body; Parkinson's disease; alpha-synuclein; deep brain stimulation; subthalamic nucleus

Mesh:

Substances:

Year:  2016        PMID: 27911008     DOI: 10.1002/mds.26882

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  7 in total

1.  Probing the striatal dopamine system for a putative neuroprotective effect of deep brain stimulation in Parkinson's disease.

Authors:  Gian Pal; Bichun Ouyang; Leo Verhagen; Geidy Serrano; Holly A Shill; Charles H Adler; Thomas G Beach; Jeffrey H Kordower
Journal:  Mov Disord       Date:  2018-01-30       Impact factor: 10.338

2.  BDNF provides many routes toward STN DBS-mediated disease modification.

Authors:  D Luke Fischer; Caryl E Sortwell
Journal:  Mov Disord       Date:  2018-11-15       Impact factor: 10.338

3.  Striatal Afferent BDNF Is Disrupted by Synucleinopathy and Partially Restored by STN DBS.

Authors:  Kathryn M Miller; Joseph R Patterson; Joseph Kochmanski; Christopher J Kemp; Anna C Stoll; Christopher U Onyekpe; Allyson Cole-Strauss; Kathy Steece-Collier; Jacob W Howe; Kelvin C Luk; Caryl E Sortwell
Journal:  J Neurosci       Date:  2021-01-20       Impact factor: 6.167

Review 4.  Novel targeted therapies for Parkinson's disease.

Authors:  Theodora Ntetsika; Paraskevi-Evita Papathoma; Ioanna Markaki
Journal:  Mol Med       Date:  2021-02-25       Impact factor: 6.354

5.  Serum neurofilament indicates that DBS surgery can cause neuronal damage whereas stimulation itself does not.

Authors:  Lisa Klingelhoefer; Björn H Falkenburger; Anika Frank; Jonas Bendig; Iñaki Schniewind; Witold H Polanski; Stephan B Sobottka; Heinz Reichmann; Katja Akgün; Tjalf Ziemssen
Journal:  Sci Rep       Date:  2022-01-27       Impact factor: 4.379

6.  Post-mortem brain histological examination in the substantia nigra and subthalamic nucleus in Parkinson's disease following deep brain stimulation.

Authors:  Srestha Mazumder; Anita Y Bahar; Claire E Shepherd; Asheeta A Prasad
Journal:  Front Neurosci       Date:  2022-09-14       Impact factor: 5.152

Review 7.  How Does Deep Brain Stimulation Change the Course of Parkinson's Disease?

Authors:  Philipp Mahlknecht; Thomas Foltynie; Patricia Limousin; Werner Poewe
Journal:  Mov Disord       Date:  2022-05-12       Impact factor: 9.698

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.